ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Oramed Pharmaceuticals, Inc. ?
1
The company has declared positive results in Jan 70 after 3 consecutive negative quarters
- PRE-TAX PROFIT(Q) At USD 6 MM has Grown at 197.85%
- NET PROFIT(Q) At USD 6.15 MM has Grown at 187.12%
- RAW MATERIAL COST(Y) Fallen by 0% (YoY)
2
With ROE of -20.08%, it has a risky valuation with a 0.64 Price to Book Value
- Over the past year, while the stock has generated a return of 22.55%, its profits have fallen by -376.4%
3
High Institutional Holdings at 21.42%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 22.55% in the last 1 year, much higher than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Oramed Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Oramed Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Oramed Pharmaceuticals, Inc.
10.57%
0.72
49.01%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-5.90%
EBIT Growth (5y)
-1.24%
EBIT to Interest (avg)
-19.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.01
Tax Ratio
7.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
21.42%
ROCE (avg)
0
ROE (avg)
2.34%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.64
EV to EBIT
2.78
EV to EBITDA
2.81
EV to Capital Employed
-3.84
EV to Sales
-19.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-20.08%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
PRE-TAX PROFIT(Q)
At USD 6 MM has Grown at 197.85%
NET PROFIT(Q)
At USD 6.15 MM has Grown at 187.12%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET SALES(9M)
Higher at USD 2 MM
OPERATING PROFIT(Q)
Highest at USD -2.46 MM
EPS(Q)
Highest at USD 0.31
-11What is not working for the Company
NET PROFIT(HY)
At USD -1.49 MM has Grown at -113.88%
ROCE(HY)
Lowest at -14.57%
DEBT-EQUITY RATIO
(HY)
Highest at -62.79 %
Here's what is working for Oramed Pharmaceuticals, Inc.
Net Sales
At USD 2 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 6 MM has Grown at 197.85%
over average net sales of the previous four periods of USD -6.13 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 6.15 MM has Grown at 187.12%
over average net sales of the previous four periods of USD -7.06 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Profit
Highest at USD -2.46 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
EPS
Highest at USD 0.31
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Net Sales
Higher at USD 2 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Oramed Pharmaceuticals, Inc.
Debt-Equity Ratio
Highest at -62.79 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
